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In stem cell biology, there is a growing need for advanced technologies thatmay help to unravel themolecular
mechanisms of self-renewal and differentiation. Proteomics, the comprehensive analysis of proteins, is such
an emerging technique. To facilitate interactions between specialists in proteomics and stem cell biology,
a new initiative has been undertaken, supported by the Human Proteome Organization (HUPO) and the
International Society for Stem Cell Research (ISSCR). Here we present the Proteome Biology of Stem Cells
Initiative (PBSCI) and report on its goals and future activities.Stem cells, and especially embryonic stem cells (ESCs), receive
broad attention in scientific literature and in the more popular
media. This has been inspired by their unique properties: the po-
tential to self-renew and to differentiate into multiple lineages.
For human embryonic stem cells (hESCs), this is the potential
to form all cells in the adult body once they receive the proper
signals. The ability to control and direct differentiation in vitro
would offer opportunities to develop treatments for diseases
that cannot be treated today, especially in the area of regenera-
tive medicine where the aim is to replace damaged tissue. How-
ever, there are still many challenges before hESCs can be safely
used for clinical applications. For instance, at present culturing of
hESCs still routinely depends on feeder cells of nonhuman origin
to maintain karyotypic stability. Considering the many chal-
lenges in stem cell biology, there is a continuous need for the im-
plementation of cutting-edge techniques. The field of proteo-
mics has matured immensely in recent years (Cox and Mann,
2007;Maltman andPrzyborski, 2007), now allowing investigation
at reasonable throughput in all areas of cell biology. A growing
number of scientists have as a result started to chart the pro-
teome of individual primary stem cells and stem cell lines and
their differentiated derivatives, in order to define a subset of
stem cell-specific proteins or to identify differentiation-specific
proteins that can be used as benchmarks for the intermediate
or terminal steps of stem cell differentiation. Importantly, recent
work on stem cells and many other systems using proteomics
has shown that transcriptome analyses cannot fully explain de-
velopmental changes, most likely because they are unable to de-
tect posttranslational processes such as protein modifications
and protein-protein interactions. These can only be discovered
systematically through proteomic approaches.At present, stem cell biology and proteomics are both highly
specialized scientific domains, rarely united in one person or
even in one lab. Moreover, specialists from each field seldom
meet. Thus, crucial opportunities are missed for setting priorities
and goals and maintaining consistent and optimized standards
for research where these fields intersect, essential for effective
comparison of experimental data across different labs. The
only way to bridge this gap and derive optimal benefit from
what each field has to offer is to bring together the specialists
from both fields to discuss needs, possibilities, requirements,
and conditions that will have to be resolved before collaborative
efforts can be successful. For an effective use of proteomics
technologies in the area of stem cell biology, the dialog between
stem cell researchers and proteomics expertsmust have a clarity
and depth that enables the best possible use of high-end
technologies for the research at hand. To this end, the Human
Proteome Organization (HUPO) and the International Society
for Stem Cell Research (ISSCR) have established an alliance to
provide a platform for collaboration and communication
between scientists in each organization (Heck et al., 2007).
Although the initiative is still in its infancy, joint meetings at the
5th ISSCR Annual Meeting, head in Cairns (June 17–20, 2007),
and the HUPO 6th World Congress, held in Seoul (October
6–10, 2007), have already proved fruitful in developing an optimal
model for cooperation between ISSCR and HUPO within the
context of HUPO’s ‘‘Proteome Biology of Stem Cells’’ initiative.
At the meeting in Cairns, Paul Simmons, ISSCR President
(2006–2007), welcomed the initiative and stressed the impor-
tance of the systematic study of stem cells by proteomic analy-
ses. C.M. (Hubrecht Institute, The Netherlands) then described
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ing and promoting proteomics through international cooperation
and collaborations by fostering the development of new technol-
ogies, techniques, and training. HUPO currently supports a
number of scientific initiatives (for details see http://www.hupo.
org/research). Bearing this in mind, the importance of having
investigators from the HUPO and ISSCR organizations present
at both the HUPO and ISSCR annual flagship congresses was
emphasized. Joint sessions at the annual meetings of both
bodies were considered the best means of disseminating best
practice. There was an acute awareness of the need for defined
objectives to be realized with milestones set by both communi-
ties for the required advances. The discipline imposed by the
HUPO validation and frameworkwill enable stem cell proteomics
to advance more rapidly for mutual benefit and to accelerate
translation of stem cell research into stem cell therapies. A.D.T.
(University of Manchester, UK) described the state of the art
for proteomics at present. Mass spectrometry is now at a level
of refinement that will allow the detection of peptides at the
low femtomole level with relative quantification of proteins in
their thousands being a feasible proposition. Studies with differ-
entiating ESCs from the laboratory of I.L. (Mount Sinai Medical
Center, USA) showed the detection and quantification of low-
abundance transcription factors, e.g., Oct4, Sox2, and Nanog,
were feasible. However, it has been stressed that this is abso-
lutely dependent on appropriate preparation and fractionation
upstream of analysis. Due to the advanced proteomic technol-
ogy now available, it was possible to classify and characterize
different populations of cells, including hESCs, by looking at
the relative expression of proteins in these lines. This could
include the identification and relative quantification of cell
surface markers. Proteomic approaches also allow the analysis
and relative (or absolute) quantification of posttranslational
modifications such as acetylation and phosphorylation. These
techniques can be employed to investigate mechanisms and
pathways involved in differentiation of the murine ESC and
hESC lines. Previously, analysis of differentiating cells has
been performed at the genomic level where networks can be
effectively described. Proteomics allows these network analyses
to be moved to the protein level where protein interaction
networks can be described, as can protein posttranslational
modification. An important point to emphasize at this time is
the need for quality control practices on cell lines and sample
preparation in any proteome or transcriptome study.
I.L. and C.M. described their systematic proteomics studies.
Ongoing work in I.L.’s laboratory looked at the level at which pro-
tein expression was regulated during hESC differentiation.
Changes in over 1500 proteins had been quantified. These
data have been associated with mRNA changes, chromatin
immunoprecipitation analysis of genes associated with histone
acetylation and chromatin modification, plus promoter loading
of RNA polymerase II. With the use of doxocyclin-inducible
siRNA against Nanog (Ivanova et al., 2006) to induce differentia-
tion, it was shown that 40% of nuclear proteins have altered
expression levels with no prior change in mRNA expression,
chromatin configuration, or RNA polymerase II binding to the
appropriate promoter. C.M. described her collaborative efforts
with A.H. and J.K. (Utrecht University, The Netherlands) in which
they performed a parallel proteomics analysis of undifferentiated216 Cell Stem Cell 2, March 2008 ª2008 ISSCRhESCs and mouse ESCs with differentiated cells to obtain ESC-
specific protein markers (Van Hoof et al., 2006). The agreement
in protein expression levels between mouse and human stem
cells was remarkably low. These examples highlight the need
for further proteome analysis. Susan Nilsson (Australian Stem
Cell Centre, Australia) and Paul Simmons (University of Texas,
USA) have also acquired data that showed adult stem cell
proteomes cannot be defined from microarray data alone,
confirming earlier studies (Unwin et al., 2006). A further under-
standing of hematopoietic stem cell differentiation therefore
requires a proteomic and phosphoproteomic analysis in order
to understand normal and leukemic stem cell development.
M.P. (University of Southern California, USA) described a
further collaborative opportunity for ESC research with proteo-
mics: the International Stem Cell Initiative (ISCI). In Phase One
of this initiative, 59 hESC lines were characterized and directly
compared by using identical reagents and methodologies in
a large, collaborative community effort, supported by the Inter-
national Stem Cell Forum (Adewumi et al., 2007). In part, this
used dedicated microarray analysis, but data frommany studies
now show that the proteomic differences do not correlate
directly to mRNA differences. Cells grown and differentiated as
‘‘embryoid bodies’’ over several days were compared, and
many of the cell lines showed a high degree of similarity. How-
ever, individual investigators saw significant differences
between their cell lines in terms of their abilities to adopt different
fates during differentiation. This was not picked up by any of the
assays used; thus there are still no predictive markers of vary-
ing abilities to differentiate between the different hESC lines.
As such, this highlighted the need for new generation markers
for ‘‘primitiveness,’’ differentiation status, and tumorgenicity.
Proteomic identification of novel markers on the cell surface
that could differentiate between cell lines with specific potential-
ity is a key goal for stem cell proteomics. Ideally, such markers
would be on the cell surface. If possible, these markers would
be peptide/protein markers, against which antibodies could be
raised, as established in hematopoietic stem cell biology, but
identification and characterization of unique glycopeptides
markers using mass spectrometry was also thought to be feasi-
ble and desirable. An issue raised again here is the absolute
necessity for cells and samples to be maintained and prepared
according to best practice and standard operating procedures
prior to the engagement with proteomics techniques. The need
to implement standard operating procedures for the collection
and use of material is aided by the HUPO Proteomic Standards
Initiative (http://www.hupo.org/research/psi), which supplies
benchmark approaches for mass spectrometry. The use of the
most sophisticated equipment is required for such proteomics
ventures, and fortunately several leading proteomics laborato-
ries have signed up to this HUPO Proteomic Standards Initiative.
The HUPO 6th World Congress in Seoul was used to continue
the dialog to define the short- and long-term goals of the initiative
further. To this end, J.K. and A.H. organized a session at the
congress, well attended by both stem cell and proteomic
experts, to discuss topics that would be biologically most rele-
vant and can be realistically addressed with the current state
of technology. From the discussions at these meetings and
others, it was evident that proteomics can generate unique
data and should be used to target pressing questions in stem
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most important short-term goals should be to identify new pro-
tein cell surface markers that may be used as fingerprints for
stem cell lines or as characteristic marks for cells at a specific
stage of differentiation. Ideally, these proteins could be targeted
for cell sorting. This would confirm and expand previous studies,
such as the ISCI study (Adewumi et al., 2007), that demonstrated
that glycolipid antigens SSEA3 and SSEA4, keratan sulfate anti-
gens TRA-1-60, TRA-1-81, GCTM2, and GCT343, and protein
antigens CD9 and CD90 were expressed on the 59 hESC lines
tested. In addition, in-depth analysis of stem cell-specific signal-
ing, for instance through comprehensive phosphoproteomics
analyses, would allow a more detailed understanding of stem
cell behavior. Such studieswill benefit from a collaborative effort.
Over the next fewmonths, the discussion will focus on narrowing
down specific questions, such as the number and identity of cell
lines that should be included in such an initiative, the best growth
media and culture conditions, the proteomic techniques that
should be applied, and which labs would be interested in
contributing to such studies productively andwithin a reasonable
timeframe. Now that these issues are becoming more concrete,
this will be the basis for the agenda of future discussions. The 6th
ISSCR Annual Meeting, which will be held in Philadelphia (June11–14, 2008), will be used to model these maturing ideas in
a draft proposal, while more definitive decisions will be made
at the HUPO 7th Annual World Congress, which will be held in
Amsterdam (August 16–20, 2008). A website has been created
to report on these activities (http://www.hupo.org/research/
stemcells/) and provides further background on the initiative.
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